SCHEMBL3556525

SCHEMBL3556525

O=C(O)c1ccc(CCCc2ccccc2NS(=O)(=O)c2ccccc2F)cc1

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 8/20 0.64
PTK2B Q14289 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TAS2R14 Q9NYV8 2/20 0.46
TSHR P16473 1/20 0.46
PTGER1 P34995 1/20 0.46
PTGER4 P35408 1/20 0.46
PTGER3 P43115 1/20 0.46
PTGER2 P43116 1/20 0.46
ACLY P53396 1/20 0.46
LPAR1 Q92633 1/20 0.44
LPAR5 Q9H1C0 1/20 0.44
LIMK2 P53671 1/20 0.43
KAT6A Q92794 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3553224 0.94 SLC16A3 (0.72) SLC16A3PTK2BSMN1; SMN2TAS2R14TSHR
SCHEMBL3566806 0.90 SLC16A3 (0.60) SLC16A3PTK2BSMN1; SMN2TAS2R14PTGER1
SCHEMBL3558218 0.89 SLC16A3 (0.57) SLC16A3PTK2BSMN1; SMN2PTGER1PTGER4
SCHEMBL3561067 0.88 SLC16A3 (0.67) SLC16A3PTK2BSMN1; SMN2TSHRACLY
SCHEMBL3557081 0.85 SLC16A3 (0.66) SLC16A3PTGER1PTGER4PTGER3PTGER2
SCHEMBL3566896 0.85 SLC16A3 (0.61) SLC16A3PTGER1PTGER4PTGER3PTGER2
SCHEMBL3556182 0.85 SLC16A3 (0.68) SLC16A3TAS2R14PTGER1PTGER4PTGER3
SCHEMBL3555674 0.84 SLC16A3 (0.60) SLC16A3
SCHEMBL3566056 0.84 TSHR (0.55) SLC16A3PTK2BSMN1; SMN2TSHRKAT6A
SCHEMBL3551901 0.84 SLC16A3 (0.89) SLC16A3TSHRPTGER1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SLC16A3 425/4885PTK2B 3187/4885SMN1; SMN2 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.